Current research indicates that WT1-AS is specifically expressed in malignant tumors, and its expression level is closely related to clinicopathological parameters such as tumor size, tumor-node-metastasis (TNM) stage, and survival, indicating that it plays an important role in such malignant tumors and may serve as a new target for tumor diagnosis and treatment. Here, WT1 is linked to neoplasm.